Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | SCN1A | P35498 | 1/20 | 0.35 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.35 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.35 |
| ▸ | CYP51A1 | Q16850 | 2/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA5A | P35218 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23623948 | 0.80 | TP53 (0.41) | TP53SCN1ASCN2ASCN3ACYP51A1 | |
| SCHEMBL23623815 | 0.79 | TP53 (0.36) | TP53SCN1ASCN2ASCN3ACYP51A1 | |
| SCHEMBL23623869 | 0.75 | — | — | |
| SCHEMBL23623819 | 0.75 | TP53 (0.39) | TP53SCN1ASCN2ASCN3ACYP51A1 | |
| SCHEMBL13449655 | 0.72 | ALDH1A1 (0.53) | TP53SCN1ASCN2ASCN3ACYP51A1 | |
| SCHEMBL23623824 | 0.69 | PTGS2 (0.37) | TP53SCN1ASCN2ASCN3ACYP51A1 | |
| SCHEMBL23623916 | 0.68 | HDAC8 (0.40) | TP53SCN1ASCN2ASCN3ACYP51A1 | |
| SCHEMBL22683759 | 0.66 | CYP51A1 (0.42) | TP53SCN1ASCN2ASCN3ACYP51A1 | |
| SCHEMBL23157115 | 0.66 | TP53 (0.42) | TP53SCN1ASCN2ASCN3ACYP51A1 | |
| SCHEMBL15083519 | 0.66 | CA1 (0.42) | TP53SCN1ASCN2ASCN3ACYP51A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210207188-A1 | BETA-LACTAM COMPOUNDS AND METHODS OF USE THEREOF | THE UNIVERSITY OF HONG KONG (HK) | 2021-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210207188-A1 | BETA-LACTAM COMPOUNDS AND METHODS OF USE THEREOF | MGAM, SI, PGLS | TP53 4680/4885SCN1A 3788/4885SCN2A 3130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.